Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 5 Nov 2025 |
| Novo Nordisk submits updated proposal to acquire Metsera, Inc. | 4 Nov 2025 |
| Novo Nordisk submits proposal to acquire Metsera, Inc. | 30 Oct 2025 |
| Notice convening an Extraordinary General Meeting of Novo Nordisk A/S | 21 Oct 2025 |
| Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors | 21 Oct 2025 |
| Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio | 9 Oct 2025 |